Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapy
Chemoradiation (CRT) may modulate the immune milieu as an in-situ vaccine. Rapid dose delivery of brachytherapy has unclear impact on T-cell repertoires. HPV-associated cancers express viral oncoproteins E6/E7, which enable tracking antigen/tumor-specific immunity during CRT.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Gohar S. Manzar, Molly B. El Alam, Erica J. Lynn, Tatiana V. Karpinets, Timothy Harris, David Lo, Kyoko Yoshida-Court, Tatiana Cisneros Napravnik, Julie Sammouri, Daniel Lin, Lauren M. Andring, Julianna Bronk, Xiaogang Wu, Travis T. Sims, Geena Mathew, Ka Tags: Original Article Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | Cancer Vaccines | Cervical Cancer | Legislation | Vaccines